Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Missouri: - Saint Louis Cancer and Breast Institute-Ballwin — Ballwin, Missouri
- Central Care Cancer Center - Bolivar — Bolivar, Missouri
- Cox Cancer Center Branson — Branson, Missouri
- Saint Francis Medical Center — Cape Girardeau, Missouri
- Southeast Cancer Center — Cape Girardeau, Missouri
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Missouri: - Saint Louis Cancer and Breast Institute-Ballwin — Ballwin, Missouri
- Central Care Cancer Center - Bolivar — Bolivar, Missouri
- Cox Cancer Center Branson — Branson, Missouri
- Saint Francis Medical Center — Cape Girardeau, Missouri
- Southeast Cancer Center — Cape Girardeau, Missouri
Phase 3 Recruiting Network
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in Missouri: - Saint Louis Cancer and Breast Institute-Ballwin — Ballwin, Missouri
- Central Care Cancer Center - Bolivar — Bolivar, Missouri
- Cox Cancer Center Branson — Branson, Missouri
- Saint Francis Medical Center — Cape Girardeau, Missouri
- Southeast Cancer Center — Cape Girardeau, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …
Sponsor: Pfizer
NCT ID: NCT06152575
Sites in Missouri: - American Oncology Partners, P.A. Dba MidAmerica Cancer Care — Belton, Missouri
- MIVA Medical — Independence, Missouri
- Kansas City VA Medical Center — Kansas City, Missouri
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care — Kansas City, Missouri
Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT06158841
Sites in Missouri: - University of Missouri Hospital /ID# 261553 — Columbia, Missouri
Phase 3 Recruiting Industry
Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multip…
Sponsor: Takeda
NCT ID: NCT06980480
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05438043
Sites in Missouri: - Barnes-jewish Hospital — St Louis, Missouri
Phase 3 Recruiting Academic/Other
Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonuni…
Sponsor: St. Louis University
NCT ID: NCT03823534
Sites in Missouri: - Saint Louis University — St Louis, Missouri
Phase 2 Recruiting NIH
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06179888
Sites in Missouri: - Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
- Siteman Cancer Center at Christian Hospital — St Louis, Missouri
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting Industry
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants w…
Sponsor: Sanofi
NCT ID: NCT06356571
Sites in Missouri: - Alliance for Multispeciality Research - Kansas City- Site Number : 8400056 — Kansas City, Missouri
- Washington University- Site Number : 8400007 — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14)…
Sponsor: BeOne Medicines
NCT ID: NCT04973605
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT04634552
Sites in Missouri: - Washington University School Of Medicine — St Louis, Missouri
Phase 2 Recruiting Network
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be a…
Sponsor: Multiple Myeloma Research Consortium
NCT ID: NCT06171685
Sites in Missouri: - Washington University Medicine — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants …
Sponsor: AstraZeneca
NCT ID: NCT06106945
Sites in Missouri: - Research Site — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myelo…
Sponsor: Washington University School of Medicine
NCT ID: NCT06483100
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Industry
This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).
Sponsor: AstraZeneca
NCT ID: NCT07073547
Sites in Missouri: - Research Site — St Louis, Missouri
Phase 1 Recruiting Industry
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with…
Sponsor: AbbVie
NCT ID: NCT06896916
Sites in Missouri: - Washington University /ID# 266972 — St Louis, Missouri
Phase 1 Recruiting Academic/Other
Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years. However, despite the high prevalence of renal insufficiency in this population, pivotal…
Sponsor: Washington University School of Medicine
NCT ID: NCT06623630
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Academic/Other
Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need …
Sponsor: Washington University School of Medicine
NCT ID: NCT06185751
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
EARLY Phase 1 Recruiting Academic/Other
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additio…
Sponsor: Washington University School of Medicine
NCT ID: NCT06636175
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Academic/Other
The outcomes in patients with relapsed multiple myeloma refractory to triple-therapy (anti-CD38, immunomodulatory drugs (IMiD) and proteasome inhibitors (PI)) remain poor. These patients are eligible for chimeric antigen receptor T-cells (…
Sponsor: Washington University School of Medicine
NCT ID: NCT07200102
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Academic/Other
This is a two-arm, open-label, randomized, single-site, pilot study testing the addition of CYT107 following autologous hematopoietic cell transplant (AHCT) in patients with multiple myeloma (MM). The hypothesis of this study is that recom…
Sponsor: Washington University School of Medicine
NCT ID: NCT06523699
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Missouri: - Mercy Oncology and Hematology - Clayton-Clarkson — Ballwin, Missouri
- Central Care Cancer Center - Bolivar — Bolivar, Missouri
- Cox Cancer Center Branson — Branson, Missouri
- Mercy Cancer Center - Cape Girardeau — Cape Girardeau, Missouri
- Saint Francis Medical Center — Cape Girardeau, Missouri
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Missouri: - Children's Mercy Hospital and Clinics — Kansas City, Missouri
- Cardinal Glennon Children's Medical Center — St Louis, Missouri
- St. Louis University Medical Center — St Louis, Missouri
- Washington University St. Louis — St Louis, Missouri
- Washington University/St. Louis Children's Hospital — St Louis, Missouri